Who We are
Minghui Pharmaceutical is a global biopharmaceutical company dedicated to developing innovative medicines for the benefit of patients with diseases of largely unmet medical needs. Leveraging our expertise in medical science and the proprietary technology platforms, we are developing a rich clinical-stage pipeline including a variety of first-in-class or best-in-class drug candidates. We are committed to serving patients around the world.
•Minghui Shanghai founded with ￥80M in seed financing
•Minghui Hangzhou founded
•2000 m² R&D center operation
•The first IND approved in China
•2nd round of over $ 70M Fund
•Two clinical trials in China
•Minghui US founded
•One phase 2 study completed
•One phase 3 study approved by FDA
•3 IND approved in China
Dr. P.K. Jadhav
William Chin, M.D.
Dr. Chin is the Bertarelli Professor of Translational Medical Science and Professor of Medicine Emeritus at Harvard Medical School (HMS). Dr. Chin is formerly Executive Vice President for Science and Regulatory Advocacy and Chief Medical Officer (CMO) at Pharmaceutical Research and Manufacturers of America (PhRMA) where he led PhRMA’s continuing efforts in science and regulatory advocacy in the drug discovery and development ecosystem. Prior to PhRMA, he was the Executive Dean for Research at HMS. Before that, he was at Eli Lilly and Company last (11 years) as Senior Vice President for Discovery Research and Clinical Investigation.
Currently, he is also Senior VP for Translational Medical Science and former CMO of Frequency Therapeutics; Executive Chair, Board of Directors, Regenacy Pharmaceuticals; Board Member, A*STAR and Chair, Governing Board, National Experimental Drug Development Centre, Singapore; Chair, Scientific Advisory Board for Regenacy Pharmaceuticals, and strategic advisor and board member for a number of start-up biotechs. Dr. Chin is a Harvard-trained endocrinologist and longstanding faculty member with an extensive biography of over 300 papers, chapters and books. His career is highlighted by leadership in molecular endocrinology and translational science and medicine during his 25 years on the Harvard Medical School faculty. During this time, Bill was Chief of the Genetics Division in the Department of Medicine at Brigham and Women’s Hospital, a Howard Hughes Medical Institute Investigator and Professor of Medicine, and Obstetrics, Gynecology and Reproductive Medicine at HMS.
As a pioneering molecular endocrinologist, Bill embraced the early use of emerging DNA technology to make important discoveries regarding the structure, function and regulation of hormone genes. He has been honored with numerous awards for research, mentorship and leadership. Bill received his A.B. in Chemistry from Columbia University and his M.D. from Harvard Medical School.
GUOQING CAO, PhD.
Founder, Chairman and CEO
Bachelor in Biochemistry, Fudan University
PhD in Biochemistry, The Ohio State University, USA
Postdoc fellow of Dr. Michael Brown (Nobel Laureate), Dr. Joseph Goldstein (Nobel Laureate) and Dr. Helen Hobbs (National Academy of Science) at University of Texas, Southwestern Medical Center at Dallas
Cardiometabolic discovery scientist and management at Eli Lilly & Company
Jiangsu Hengrui Medicine, Vice President of discovery/preclinical development/translational medicine business development/portfolio management/
More than 80 papers published in peer-reviewed journals and more than 50 patents/patent applications